Fundraising Fox
/Companies
Sign in

Helicore Biopharma

Southbury, US · Founded 2020 · 5 known investors

Find your way into Helicore Biopharma

617 people in our graph share verified history with the Helicore Biopharma team — schools, employers, funds. One of them is your warm intro.

Mohan S. Iyerunlockedknows Peter DiLaura · together at Second Genome, Inc. (overlapped)
×2knows the team · via The Wilkerson Group (an IBM Company)
knows the team · via Dementia Discovery
×8knows the team · via Innovation Endeavors

Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.

BiotechHealthtech

Founders & leadership

KRKevin Russ
Kevin RussChief Executive OfficerKevin Russ is CEO of Helicore. He brings over 30 years of experience in program and project management across wireless communications and infrastructure development, with expertise in site acquisition, permitting, RF design, and 5G deployment, along with certifications as a PMP and PgMP project manager.
PDPeter DiLaura
Peter DiLauraChief Executive OfficerHe previously served as President and CEO of Initial Therapeutics and spent four years as Chief Business and Strategy Officer at Sonoma Biotherapeutics, following a stint as Entrepreneur in Residence at Third Rock Ventures. He also sits on the boards of Character Biosciences and Weave Bio and advises the Engineering Health portfolio at Innovation Endeavors.
WK
Waters KelloggNamed on SEC filing
LB
Lucas B. TurnerNamed on SEC filing
JD
Joshua DotsonNamed on SEC filing
HK
Holger KoehlerNamed on SEC filing
CB
Charles BridgeNamed on SEC filing

Investors · 5

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · funding news · fiercebiotech.com · the VCSheet dataset · Not right? Tell us

Versant VenturesreportedSan Francisco · $250K – $5M

How we know: a partner's Signal profile · press coverage · Not right? Tell us

Wellington ManagementreportedBoston · $5M – $50M

How we know: fiercebiotech.com · Not right? Tell us

Also in the syndicate · 1

Versantlead

Funding

SEC filings, press & company announcements

$2M disclosed across 1 of 3 rounds · 2020–2025

▶$2MraisedApr 2020 · 1 investors · Telecommunications
Rule 506(b)
Officers, directors & promoters on the filing
  • Waters KelloggDirector
  • Lucas B. TurnerDirector
  • Joshua DotsonDirector
  • Kevin RussExecutive Officer, Director
  • Holger KoehlerDirector
  • Charles BridgeDirector
Offering amount
$2M
Amount sold
$2M
Minimum investment
$2M
First sale
Apr 2020
Incorporated
Limited Liability Company, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions - BioSpacebiospace.com · Jan 2025

Frequently asked questions

What does Helicore Biopharma do?
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
Who are Helicore Biopharma's investors?
Helicore Biopharma's investors include Longitude Capital, OrbiMed, Versant Ventures, Wellington Management.
How much funding has Helicore Biopharma raised?
Helicore Biopharma has disclosed $2M raised across 1 of its 3 known rounds.
Where is Helicore Biopharma headquartered?
Helicore Biopharma is headquartered in Southbury, US.